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A B S T R A C TObjective: To determine the cost-effectiveness of lipid-lowering ther-
apy in the secondary prevention of cardiovascular events in the
Philippines. Methods: A cost-utility analysis was performed by using
Markov modeling in the secondary prevention setting. The models
incorporated efficacy of lipid-lowering therapy demonstrated in rando-
mized controlled trials and mortality rates obtained from local life
tables. Average and incremental cost-effectiveness ratios were obtained
for simvastatin, atorvastatin, pravastatin, and gemfibrozil. The costs of
the following were included: medications, laboratory examinations,
consultation and related expenses, and production losses. The costs
were expressed in current or nominal prices as of the first quarter of
2010 (Philippine peso). Utility was expressed in quality-adjusted life-
years gained. Sensitivity analyses were performed by using variations in
the cost centers, discount rates, starting age, and differences in utilitysee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.01.003
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y of the Philippines Manila, Paz Mendoza Buildingweights for stroke. Results: In the analysis using the lower-priced
generic counterparts, therapy using 40 mg simvastatin daily was the
most cost-effective option compared with the other therapies, while
pravastatin 40 mg daily was the most cost-effective alternative if the
higher-priced innovator drugs were used. In all sensitivity analyses,
gemfibrozil was strongly dominated by the statins. Conclusions: In
secondary prevention, simvastatin or pravastatin were the most cost-
effective options compared with atorvastatin and gemfibrozil in the
Philippines. Gemfibrozil was strongly dominated by the statins.
Keywords: cholesterol, cost-effectiveness, cost-utility, lipid-lowering
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In the Philippines, ischemic heart disease and cerebrovascular
disease accounted for 10% and 5% of total deaths, respectively, in
2002 while in 2004, heart and vascular system diseases were the
top two causes of mortality, accounting for 85.7 and 62.5 deaths
per 100,000, respectively [1,2]. Moreover, in 2009, diseases of the
heart and the cerebrovascular system were the top two causes of
mortality, accounting for 21% (100,908) and 11.8% (56,670) of
deaths, respectively [3]. In a global case-control study that included
the Philippines, dyslipidemia and smoking were found to be the
two most important risk factors for acute myocardial infarction [4].
Meanwhile, in the national nutrition and health surveys, the
prevalence of hypercholesterolemia increased by twofold between
1998 and 2003 [5]. Unfortunately, this has further increased in the
2008 survey, which showed that 10% of Filipino adults have high
total cholesterol levels while 14.6% have high triglyceride levels [6].
Thus, the problem of dyslipidemia needs to be addressed.
The cost of treating dyslipidemia represents an additional eco-
nomic burden to a population in which four out of five live below the
poverty line [4]. Also, the national government provision for health
care delivery is limited. In contrast to the World Health Organizationrecommendation of 5% of the gross national product to be spent on
health care, the national health care expenditure was 3.3% of the
gross national product in 2006 [2]. Furthermore, health care is
usually obtained through out-of-pocket payments as seen in 2006
when it represented 56% of the total health care expenditures [7].
Facedwith the increasing problems of dyslipidemia as a cardio-
vascular disease risk factor, the country’s limited health resources,
variations in clinical practice, and the difficulty of adopting foreign
clinical practice guidelines, the Philippine Heart Association
together with the International Clinical Epidemiology Network
developed and published in 2005 ‘‘The Clinical Practice Guidelines
for the Management of Dyslipidemia in the Philippines’’ [4].
However, increasing awareness that effectiveness alone is not
sufficient for decision making, whether in the individual patient
setting or in the broader context of policymaking, a cost-
effectiveness analysis (CEA) of the local guidelines was per-
formed in 2008 [8]. This CEA reported the cost of preventing
mortality and the cardiovascular events reported in the clinical
trials expressed as cost-effectiveness ratios (CERs), either as
average CERs or incremental CERs (ICERs). Several methods were
used to determine the ICERs including Markov modeling, though
in a limited manner.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
conflicts of interest with regard to the content of this article.
, MScE, MHE, Department of Clinical Epidemiology, College of
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icine law and maximum drug retail prices of some of the
essential medicines led to a decrease in the cost of lipid-
lowering drugs by as much as 50%. Because the cost of medicines
is a significant factor in the computation of ICERs of pharmaco-
logic options, a drastic change in the cost of drugs would result in
a significant change in the ICERs for secondary prevention.
In view of these issues, this study was undertaken with the
following objectives: General Objective: To determine the cost-
effectiveness of the lipid-lowering therapy in the secondary preven-
tion setting in the Philippines using the societal perspective. The
specific objectives were to determine 1) the average and incremental
cost-effectiveness ratios of the lipid-lowering therapy in the second-
ary prevention setting and 2) the most cost-effective option among
the lipid-lowering therapies in the secondary prevention level.
This economic analysis chose the societal perspective because
it reflects a broader evaluation of both costs and effects (health
and nonhealth aspects) of an intervention or program.Methods
Effectiveness data were obtained from randomized controlled
trials in the secondary prevention setting. The trials that were
appraised by the technical research committee of the local
guideline developers were considered. This appraisal included
issues on the applicability of foreign studies to the local setting
by utilizing the International Clinical Epidemiology Network
Guideline Development Cycle, otherwise known as the Knowl-
edge Management Plus [4]. Knowledge Management Plus incor-
porated included questions on ‘‘equity lens,’’ that is, those
involving access to a particular health care intervention [4].
However, the trials must include the following end points:
nonfatal myocardial infarctions, death due to coronary heart
disease, stroke, and revascularization. Based on these criteria,Table 1 – Summary of the societal costs for the diagnosi
Costs identified Measurement of cost pe
1. Health care resources
consumed
Cost per single adverse event multip
number of adverse events
- Costs of treating adverse
events
2. Cost of patient/patient’s
family resources
a. Cost of medicines Unit price of specific lipid-lowering a
days in a year (365)
b. Laboratory costs Unit price (charge) multiplied by the
screening tests in a year
c. Doctor’s fees Outpatient fees multiplied by the nu
year
d. Travel costs P100–P400 per visit  the number of
3. Production losses
a. Labor productivity 1/2 d/visit multiplied by the number
b. Cost of leisure time Same time spent as above (for those
work time in doing outpatient con
4. Cost due to the consumption
of other resources/sectors
Number of consultations for lifestyle
maneuvers
- lifestyle modification
maneuvers education
programs
- time spent on exercise Number of hours spent
GDP, gross domestic product.
 Unit cost of medicine  number used/day  365 (dose is 1 tablet/d; thuthe following were chosen to be the basis for this economic
analysis: 1) MRC/BHF Heart Protection Study of cholesterol low-
ering with simvastatin in 20,536 high-risk individuals: a rando-
mized placebo-controlled trial [9]; 2) Treatment with atorvastatin
to the National Cholesterol Education Program goal versus usual
care in secondary heart disease prevention: the GREek Atorvas-
tatin and Coronary-heart-disease Evaluation (GREACE) study [10];
3) Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of
initial cholesterol levels (the Long-term Intervention with Pravas-
tatin in Ischaemic Disease (LIPID) study [11]); and 4) The Veterans
Affairs High-density lipoprotein cholesterol Intervention Trial
(VA-HIT) study [12]: Gemfibrozil for the secondary prevention of
coronary heart disease in men with low levels of cholesterol.Description of Competing Alternatives
Using the above-mentioned trials, the pharmacologic options
analyzed in this article were comparisons of any of the following
pharmacologic maneuvers versus placebo:1.s a
r pa
lied
gen
fre
mbe
vis
of v
wh
sul
m
s, uSimvastatin 40 mg/d
2. Pravastatin 40 mg/d
3. Atorvastatin 20 mg/d
4. Gemfibrozil 1200 mg/dDaily doses of 10, 20, 40, and 80 mg were used in the GREACE
study [9]; however, the 20 mg daily dose was chosen because 85%
of the study population received this dose.Identification, Measurement, and Valuation of costs
The classification of cost recommended by Drummond et al. [13]
into four types was utilized in this study and is described below.nd treatment of dyslipidemia.
tient Valuation of costs
by the Depends on the adverse effect identified (no
significant ones identified)
t multiplied by Prices obtained from the biggest drugstore in
the country
quency of Unit price/charge from laboratories range;
minimum–maximum
r of visits in a Outpatient consultations fees (50%–100%);
minimum–maximum fees
its in a year Transportation charges by laboratory doing
home visits
isits in a year GDP/average number of employed persons
o will not use
tations)
Overtime wage rate (150% of minimum daily
wage in the national capital region)
odification Cost of consultation ¼ 0 (already part in the
outpatient consultation – doctor’s fees)
0 (leisure time not given a cost or value)
nit cost  365).
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Philippine peso using current prices as of the first quarter of 2010.
Health care resources consumed
This refers to the costs of setting up and running the program
(variable and fixed or overhead costs), as well as the possible
adverse events attributable to the program. In this article, how-
ever, this type of cost was not included because there is no need
to create a dedicated facility for the screening and management
of dyslipidemia. Patients’ consultations were done in existing
outpatient clinics. Moreover, laboratory examinations for screening
and monitoring of lipid levels and transaminases do not require
setting up additional laboratory facilities. Furthermore, costs for
clinic visits and laboratory examinations were included in out-of-
pocket payments because the burden of these costs was on
patients or their families. However, the costs of consultation for
the lifestyle modification maneuvers were included in the fourth
or last category of cost.
The costs of treating possible adverse effects were not
included because no significant adverse events were reported
for simvastatin, atorvastatin, pravastatin, and gemfibrozil.
Cost of patient/patient’s family resources
This refers to out-of-pocket payments incurred by the patient(s)
and his family as well as value of resources allotted to the
treatment process. Out-of-pocket payments included cost of
medicines, laboratory examinations, doctor’s fees, and transpor-
tation costs of going to and from the doctor’s clinics. Some
studies recommended using international prices of medicines,
while others used the wholesale acquisition costs [14,15]. In
contrast, this study used the prices obtained from the biggest
drugstore chain in the country (with branches nationwide, con-
trols 80% of the retail market, and claims uniform pricing
scheme) [16]. Prices instead of cost of medicines were used
because they represented the real costs borne through out-of-
pocket payments. In instances in which a particular medicine
was not available in this drugstore chain, the price was obtained
from another store whose drug prices were almost similar to
those of the biggest drugstore chain.
In view of the availability of lower-priced generic medicines, a
list of the prices of similar generic medications from the above
drug store chain was obtained. The lowest-priced drugs were
used in the base-case analysis, while those of the innovator
brands (most expensive) were used in the sensitivity analyses.Table 2 – Average and incremental cost-effective ratios o
6% discount rate).
Strategy Cost Incremental cost Effect
Simvastatin Php 77K 5.34 QALY
Pravastatin Php 96K Php 19K 5.10 QALY
Atorvastatin Php 100K Php 23K 5.53 QALY
Gemfibrozil Php 101K Php 1K 4.28 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness rat
Table 3 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect
Simvastatin Php 77K 5.34 QALY
Atorvastatin Php 100K Php 23K 5.53 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratThe cost of laboratory examinations was obtained using
charges (rather than cost, again because these were the real cost
borne through out-of-pocket payments) from several hospitals or
outpatient private laboratories. Included in the outpatient labora-
tories surveyed was the laboratory in which the lipid profile test
results were proven to be reliable and accurate. Charges from this
laboratory were found to be in the lower-priced range and almost
simulated the charges from the government hospital; thus, these
were used for the base-case analysis. The charges from a tertiary
private hospital were used in the sensitivity analysis.
Doctors’ professional fees ranged from Php300 to Php600 per
visit. The lowest came from the health maintenance organiza-
tions fees to internists, while the highest fees came from a
random survey of outpatient fees in private clinics of internists
(with or without subspecialization). The lowest of the doctors’
fees was used for the base-case analysis.
It may be argued that the doctors’ fees should not be
attributed to the treatment of dyslipidemia alone, because the
patients are also consulting for other conditions. However,
because the cost for consultation for lifestyle modification
maneuvers was not included (see fourth category of cost), the
full amount of the doctor’s fees was used.
Transportation cost was estimated to be in the range of P100
to P400 per visit. The lowest of the range was obtained from the
charges imposed by a laboratory that conduct home visits for
purposes of extracting the specimen for laboratory examinations.
The highest of the range was estimated from the average taxi fare
to and from the clinic.
Production losses
The value of production losses had been referred to as ‘‘wealth lost
to society due to disease’’ [17]. However, the term ‘‘productivity
cost’’ was recommended by the US Panel on Cost-Effectiveness in
Health and Medicine, which refers to ‘‘the costs associated with
lost or impaired ability to work or to engage in leisure activities
due to morbidity and lost economic productivity due to death’’ [18].
Valuation of productivity cost or production losses varies.
These issues are discussed lengthily in the CEA of the local
guidelines [7]. Productivity cost or labor productivity is defined by
the Organization for Economic Cooperation and Development
(and adopted by the Department of Labor and Employment of the
Philippines) as ‘‘the ratio of a volume measure of output to a
volume measure of input’’ [19]. Thus, labor productivity was
computed by dividing the gross domestic product by the number
of employed persons (average of four survey rounds of the Laborf lipid-lowering therapy (base-case analysis;
Incremental effect Average CERs ICERs
14,452/QALY
0.25 QALY 18,836/QALY Dominated
0.19 QALY 18,125/QALY 121,654/QALY
1.25 QALY 23,577/QALY Dominated
ios; QALY, quality-adjusted life-year.
Incremental effect Average CERs ICERs
14,452/QALY
0.19 QALY 18,125/QALY 121,654/QALY
ios; QALY, quality-adjusted life-year.
Fig. 1 – Cost-effectiveness analysis (Table 2).
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goods and services produced domestically; the sum of gross
value added of all resident institutional units engaged in produc-
tion (plus any taxes, and minus any subsidies, on products not
included in the values of their outputs)’’ [20]. Production losses
from work due to outpatient consultations and laboratory deter-
minations for dyslipidemia were measured as the daily cost of
labor productivity multiplied by the number of days of absences
incurred during the treatment period.
However, not all employers allow their workers to have their
outpatient medical consultations on regular working hours. In
these instances, workers spent part of their leisure time for
medical purposes; thus, the cost of leisure time was determined
in place of the cost of labor productivity. The value of leisure time
may range ‘‘from zero to average earnings, to average overtime
earnings (time and a half or double time),’’ as stated by Rubins
et al. [12]. In this article, the cost of leisure time was computed on
the basis of an individual’s average overtime earnings. This was
calculated as 150% of the average minimum daily wage. The
average minimum daily wage in the national capital region as
prescribed by the Department of Labor and Employment of the
Philippines in 2008 was used in this study [20].
The time spent for outpatient consultation and laboratory
examinations was estimated to be about 4 hours. Hence, wage for
half a day’s work was used whether the basis of computation was
either cost of labor productivity or cost of leisure time.
Cost due to consumption of other resources/sectors
This last category includes the cost of educating the patients with
regard to lifestyle modifications and the cost of time spent on
physical exercises. Some may argue that activities such as biking
and the like are not only for exercise purposes but are pleasurable
ways of spending ‘‘quality’’ time with family members or friends
as well; hence, the monetary cost for ‘‘exercise time’’ was not
determined. However, lifestyle modification maneuvers can be
pursued through individual consultations or education cam-
paigns. Advice on lifestyle modification maneuvers can be incor-
porated during physician visits without additional cost unless the
patients are referred to nutritionists or dieticians. In addition,
some education programs are carried out by government and
nongovernment organizations on certain occasions. Participants,
however, in such programs are not exclusive to the secondary
prevention setting. In view of these, no cost for the fourth
category was included in the base-case analysis.
Consequences/Outcomes Measured
The clinical end points required for inclusion in this article were
nonfatal myocardial infarctions, death due to coronary heart
disease, stroke, and revascularization. Utilities or health gains in
the above outcomes were measured in a metric known as
quality-adjusted life-years (QALYs), which were obtained from
previous studies [21,22]. The values ranged from zero (0) to one
(1), with 0 equating to death and 1 to full health [12].Table 4 – Average and incremental cost-effective ratios o
discount rate).
Strategy Cost Incremental cost Effect
Simvastatin Php 135K 6.02 QALY
Gemfibrozil Php 150K Php 15K 4.75 QALY
Pravastatin Php 154K Php 18K 5.72 QALY
Atorvastatin Php 164K Php 28K 4.28 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratUse of Markov Models for the Secondary Prevention Setting
‘‘A decision model is usually developed to assist decision-makers
in making choices relating to the evaluated options. Typically, the
objective of a decision model is to obtain a clearer understanding
of the relationships between incremental costs and their con-
sequences’’ [23]. Moreover, modeling is an ‘‘explicit, quantitative,
prescriptive approach to medical decision-making and allows
both clinical and economic consequences of medical actions and
attitudes to be analyzed under conditions of uncertainty’’ [24].
Although modeling is not easy, ‘‘economists often build models
that make simplifying assumptions to make the problem tract-
able, but hopefully capture sufficient detail to provide reasonably
valid predictions of future events’’ [25].
In this study, the Markov models incorporated effectiveness
data obtained from randomized controlled trials of the four lipid-
lowering therapy with estimates of QALY weights and mortality
rates in the local setting (life tables) [26]. Finally, modeling was
accomplished through the use of the TreeAge software [27].
Discount Rates
The World Health Organization Guide for CEA recommends a
discount rate of 3% for both costs and effects (or outcomes) in the
base-case analysis and 6% for costs and 0% for effects in the
sensitivity analysis [14]. However, other economists recommend
using 3% and 5% in the base-case analysis and include 0%, 3%,
and 5% in the sensitivity analysis (for both costs and effects) [12].
In this article, 3% and 6% were used in the base-case and
sensitivity analyses for both costs and effects.Results
Base-Case Analysis
The base-case analysis included the following assumptions:
1) lowest range of costs, 2) 6% discount rate for costs and effects,
and c) 35 years as starting age. Moreover, the utility weight for
moderate stroke (0.68) [22] was used, and when data for fatal stroke
were lacking, it was assumed to be 20% (fatal strokes were reportedf lipid-lowering therapy (base-case analysis; 3%
Incremental effect Average CERs ICERs
22,508/QALY
1.27 QALY 31,633/QALY Dominated
0.30 QALY 26,893/QALY Dominated
0.23 QALY 26,182/QALY 122,990/QALY
ios; QALY, quality-adjusted life-year.
Table 5 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect Incremental effect Average CERs ICERs
Simvastatin Php 135K 6.02 QALY 22,508/QALY
Atorvastatin Php 164K Php 28K 6.25 QALY 0.13 QALY 26,182/QALY 122,990/QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life-year.
Table 6 – Average and incremental cost-effective ratios of lipid-lowering therapy (sensitivity analysis; highest
value in all cost centers; 6% discount rate).
Strategy Cost Incremental cost Effect Incremental effect Average CERs ICERs
Pravastatin Php 145K 5.10 QALY 28,452/QALY
Atorvastatin Php 174K Php 29K 5.53 QALY 0.44 QALY 31,485/QALY 66,757/QALY
Simvastatin Php 181K Php 7K 5.34 QALY 0.19 QALY 33,903/QALY Dominated
Gemfibrozil Php 428K Php 253K 4.28 QALY 1.25 QALY 99,793/QALY Dominated
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life-year.
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there is no country-specific data for fatal strokes in the Philippines
(data obtained through personal communication with a neurologist
revealed that in a study conducted in a tertiary government hospital
on noncardioembolic ischemic strokes, mortality after first stroke
and second stroke was 11% and 18%, respectively).
The corresponding CERs (average) and ICERs are seen in
Tables 2 and 3. The comparator for the CERs is the specific drug
versus placebo, while for the ICERs, the pharmacologic options
were compared as to their incremental cost and QALYs. This
analysis showed that simvastatin was the most cost-effective
option and that it dominated the option of using pravastatin
because the latter cost more and had less QALYs. In addition,
gemfibrozil was dominated by atorvastatin. However, if atorvas-
tatin would be used instead of simvastatin, the incremental cost
would be Php 121,654 for every QALY gained.
The cost-effectiveness frontier (Fig. 1) links the ICERs of the
different options. Gemfibrozil and pravastatin are easily seen as
the dominated options because they lie above and to the left
(northwest) of the other options (simvastatin and atorvastatin).
The slope of the line connecting simvastatin and atorvastatin
represents the ICER of choosing atorvastatin over simvastatin
(Php 121,654 for every QALY gained).Table 7 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect
Pravastatin Php 145K 5.10 QALY
Atorvastatin Php 144K Php 29K 5.53 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness rat
Table 8 – Average and incremental cost-effective ratios o
cost of drugs, 6% discount rate).
Strategy Cost Incremental cost Effect
Pravastatin Php 96K 5.10 QALY
Atorvastatin Php 121K Php 25K 5.53 QALY
Simvastatin Php 130K Php 9K 5.34 QALY
Gemfibrozil Php 386K Php 265K 4.28 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratSensitivity Analysis
Sensitivity analyses could be one-way or multiway. One-way
sensitivity analysis means that one variable was changed during
the analysis, while multiway analysis refers to changing more
than one at a time.
One-way sensitivity analysis using different utility weights for
stroke (minor to severe) resulted in similar CERs and ICERs at the
same discount rate of 6%.
The results using 3% discount rate are shown in Tables 4 and
5. This analysis showed that both gemfibrozil and pravastatin
were dominated by simvastatin. Moreover, the incremental
cost of choosing atorvastatin over simvastatin would be Php
122,990 for every additional QALY gained. As expected, as com-
pared with the base-case analysis, changing the discount rate
resulted in a significant change in the average CERs, but not the
ICERs. Tables 6 and 7 show the results when the highest value in
the range of costs for all cost centers and 6% discount rate were
used. If the cost of medicines was the only variable that was
changed, that is, the lowest value was maintained for the other
cost centers, and the discount rate at 6%, the magnitude
of the change in CERs and ICERS was large. This proved that
the cost of medicines was a key determining factor for the CERs
and ICERs.Incremental effect Average CERs ICERs
28,452/QALY
0.44 QALY 31,485/QALY 66,757/QALY
ios; QALY, quality-adjusted life-year.
f lipid-lowering therapy (sensitivity analysis, highest
Incremental effect Average CERs ICERs
18,836/QALY
0.44 QALY 21,870/QALY 57,142/QALY
0.19 QALY 24,288/QALY Dominated
1.25 QALY 90,177/QALY Dominated
ios; QALY, quality-adjusted life-year.
Table 9 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect Incremental effect Average CERs ICERs
Pravastatin Php 96K 5.10 QALY 18,836/QALY
Atorvastatin Php 121K Php 25K 5.53 QALY 0.44 QALY 21,870/QALY 57,142/QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life-year.
Table 10 – Average and incremental cost-effective ratios of lipid-lowering therapy (sensitivity analysis,
starting age ¼ 45 y, 6% discount rate).
Strategy Cost Incremental cost Effect Incremental effect Average CERs ICERs
Simvastatin Php 119K 5.27 QALY 22,508/QALY
Gemfibrozil Php 134K Php 15K 4.23 QALY 1.04 QALY 31,633/QALY Dominated
Pravastatin Php 135K Php 17K 5.03 QALY 0.24 QALY 26,893/QALY Dominated
Atorvastatin Php 143K Php 24K 5.46 QALY 0.19 QALY 26,182/QALY 130,389/QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life-year.
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alone or of all the cost items, the most cost-effective option
shifted from simvastatin to pravastatin. Moreover, both simvas-
tatin and gemfibrozil were dominated by atorvastatin. However,
choosing atorvastatin over pravastatin would entail an incre-
mental cost of Php 66,757 (Tables 6 and 7) or Php 57,142 (Tables 8
and 9) for every QALY gained.
The last sensitivity analysis generated involved changing the
initial age of the population, that is, from 35 years to 45 years,
when it entered the model. This starting age was chosen because
it is generally accepted that the majority of patients in the
secondary prevention setting are older compared with those in
the primary prevention setting. This analysis resulted in
Tables 10 and 11, in which all the assumptions for the base-
case analysis were used except for using 45 years as the entry age
in the model. The resulting most cost-effective option was the
same as in the base- case analysis, that is, simvastatin. In
addition, the incremental cost for every QALY gained if atorvas-
tatin would be used instead of simvastatin was Php 130,389.
However, using the same starting age of 45 years, but using
3% discount rate and the higher cost in all the cost centers
(same assumptions for the rest of the variables), the most cost-
effective option had again shifted to pravastatin. Simvastatin andTable 11 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect
Simvastatin Php 119K 5.27 QALY
Atorvastatin Php 143K Php 24K 5.46 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness rat
Table 12 – Average and incremental cost-effective ratios
starting age ¼ 45 y, highest cost in all, 3% discount rate
Strategy Cost Incremental cost Effect
Pravastatin Php 160K 5.64 QALY
Atorvastatin Php 194K Php 33K 6.15 QALY
Simvastatin Php 201K Php 7K 5.93 QALY
Gemfibrozil Php 468K Php 274K 4.69 QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratgemfibrozil, however, were dominated by atorvastatin, but if
atorvastatin would be used instead of pravastatin, the incremen-
tal cost for every QALY gained was Php 64,612. These CERs and
ICERs and the dominated options are shown in Tables 12 and 13
and Fig. 2.Discussion
The results of this cost-utility analysis showed that simvastatin
or pravastatin was the most cost-effective options compared
with atorvastatin and gemfibrozil. Atorvastatin, however, was
not dominated by either of the two, and if one would decide to
use atorvastatin over simvastatin or pravastatin, the ICER was
about Php 65,000 to Php 130,000.
Having obtained the above results, the most important con-
sideration is how they will affect decisions in the management of
dyslipidemia as clinicians, patients, or health policy makers.
However, before a decision is made, a threshold value (threshold
or ceiling ratio or willingness-to-pay) must be set. This value
corresponds to ‘‘shadow price per unit effectiveness in the
absence of a market’’ [28]. This means that if an ICER of Php
100,000 is set as the threshold ratio, therapies or options withIncremental effect Average CERs ICERs
22,508/QALY
0.19 QALY 26,182/QALY 130,389/QALY
ios; QALY, quality-adjusted life-year.
of lipid-lowering therapy (sensitivity analysis,
).
Incremental effect Average CERs ICERs
28,452/QALY
0.52 QALY 31,485/QALY 64,612/QALY
0.22 QALY 33,903/QALY Dominated
1.47 QALY 99,793/QALY Dominated
ios; QALY, quality-adjusted life-year.
Table 13 – CERs and ICERs (without dominated options).
Strategy Cost Incremental cost Effect Incremental effect Average CERs ICERs
Pravastatin Php 160K 5.64 QALY 28,452/QALY
Atorvastatin Php 194K Php 33K 6.15 QALY 0.52 QALY 31,485/QALY 64,612/QALY
CERs, cost-effectiveness ratios; ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life-year.
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and thus should be undertaken. In contrast, options with ICERs
greater than the ceiling ratio are considered not cost-effective
and should not be adopted. In many Western countries in which
health care delivery is usually through a third-party payor,
threshold ICERs influence health policy decisions [29–32] and
vary from country to country. In the Philippines, however, no
explicit ceiling ratio exists. Thus, faced with the above ICER of
atorvastatin, divergent views are expected, especially in a setting
in which health care provision is largely dependent on out-of-
pocket payments.
However, economists do not agree on setting threshold values.
Some countered that because this ratio could be influenced by
societies or one’s ability to pay, it may further promote health
inequity. To help resolve this issue, the WHO Commission on
Macroeconomics and Health recommended using a country’s gross
domestic product per head as the basis for the following classifica-
tion: very cost-effective, cost-effective and not cost-effective [33].
It should be noted that the cost of pravastatin remained the
same due to the availability of a single brand (the generic
counterpart) at the time of the study, leading to almost similar
CERs in the base-case and sensitivity analyses for pravastatin.
Compared with the cost of the innovator drug that was used in
the previous local economic evaluation for dyslipidemia [7], the
nominal cost of pravastatin ( first quarter of 2010) was just about
11% of the cost of the innovator drug. In view of this tremendous
drop in the cost of medicine, the corresponding CERs for pravas-
tatin significantly decreased; hence, pravastatin was the most
cost-effective option in the sensitivity analysis. This is in contrast
to the previous study in which simvastatin remained the most
cost-effective option in all the analyses among the lipid-lowering
therapies included [7]. The exact CERs of the previous study,
however, cannot be compared with the CERs of the present
analysis because of the difference in the type of economic
evaluation that was conducted. In the previous study, a cost-
consequence analysis was done to come up with a unidimen-
sional outcome required for the CEA. However, a cost-utility
analysis was performed for the present study.
Economic evaluation studies performed in several developed
countries using the same secondary prevention setting showed
different CERs and ICERs [34–37]. These variations are expected
and may be attributed to 1) difference in the identification,
measurement, and valuation of costs from country to countryFig. 2 – Cost-effectiveness frontier (Table 12).and 2) changes in disease prevalence leading to differences in the
magnitude of effects of the intervention. Inevitably, this would
lead to different CERs and ICERs in different settings. Moreover, if
a threshold ratio is adopted by some countries, imposing the
same threshold value in a developing country setting such as the
Philippines will not be realistic.Conclusions
This study showed that among the four included options of lipid-
lowering therapy in the secondary prevention level, simvastatin
was the most cost-effective option if the cost of the lower-priced
generic counterpart was used in the analysis. However, if the cost
of the higher-priced innovator drugs was used except for pravas-
tatin (of which there was just one brand available then), it was
found that pravastatin was the most cost-effective therapy. The
incremental cost of using atorvastatin either over simvastatin or
over pravastatin ranged from about Php 65,000 to Php 130,000 for
every QALY gained (base-case analysis and sensitivity analysis).
The choice of any of these three statins would be influenced by a
threshold ratio or one’s willingness to pay and one’s ability to pay.
In all analyses, gemfibrozil was strongly dominated by the
statins, being more costly and less effective.
There were several limitations recognized in this article. First,
the analysis was limited to the four lipid-lowering therapies and
the corresponding trials that serve as the basis for the economic
evaluations. Other lipid-lowering therapies that were considered
for inclusion in the analysis were rosuvastatin, ezetimibe, and
nicotinic acid. However, they were not included in the analysis
because of the lack of the required end points at the time of the
study. Moreover, the above trials were conducted in the Western
population; thus, applicability to the local setting may be proble-
matic. Although local data were used whenever possible, for
example, life tables, the existing life table is for the general
population; none exist for those in the secondary prevention
setting. The article was also constrained by the presence of many
generic counterparts and the possibility of differences in bioa-
vailability and bioequivalence. The article tried to limit the
generic counterparts to those available in the drugstore chain,
which was discussed in the Methods section.
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